(ANIK) Anika Therapeutics - Ratings and Ratios
Hyaluronic Acid, Joint Injections, Surgical Sealants
ANIK EPS (Earnings per Share)
ANIK Revenue
Description: ANIK Anika Therapeutics
Anika Therapeutics Inc (NASDAQ:ANIK) is a biotechnology company listed on the NASDAQ stock exchange, operating within the biotechnology sub-industry. The companys stock performance and financial health are critical indicators for investors and analysts.
Given the negative Return on Equity (RoE) of -38.50, it is evident that Anika Therapeutics is currently not generating profits from shareholders equity, suggesting potential operational or strategic challenges. The forward Price-to-Earnings (P/E) ratio of 833.33 indicates high growth expectations or potentially overvalued stock, considering the current lack of earnings. The Market Capitalization stands at $125.73 million, categorizing it as a small-cap company with potential for growth or volatility.
Key Performance Indicators (KPIs) to monitor for Anika Therapeutics include revenue growth, R&D expenditure as a percentage of revenue, and cash burn rate. The companys ability to bring new products to market, navigate regulatory environments, and manage its cash resources effectively will be crucial. Economic drivers such as the demand for biotechnology products, patent expirations, and competition within the industry will significantly impact Anikas financial performance.
From a trading perspective, the stocks beta of 0.637 suggests it is less volatile than the overall market, potentially appealing to risk-averse investors. However, the current price of $8.83 being closer to the 52-week low of $8.10 than the high of $26.75 indicates a significant decline in stock value over the past year, which could be due to various factors including market sentiment, product performance, or broader industry challenges.
To assess the viability of Anika Therapeutics as an investment, it is essential to analyze its product pipeline, partnerships, and financial management strategies closely. The quarterly tax provision data may offer insights into the companys tax strategies and potential impacts on profitability. Understanding these elements can provide a clearer picture of the companys future prospects and potential for return on investment.
ANIK Stock Overview
| Market Cap in USD | 125m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1993-04-29 |
ANIK Stock Ratings
| Growth Rating | -88.6% |
| Fundamental | 25.7% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -70.7% |
| Analyst Rating | 4.67 of 5 |
ANIK Dividends
Currently no dividends paidANIK Growth Ratios
| Growth Correlation 3m | -63.7% |
| Growth Correlation 12m | -93.8% |
| Growth Correlation 5y | -81.7% |
| CAGR 5y | -29.10% |
| CAGR/Max DD 3y | -0.39 |
| CAGR/Mean DD 3y | -1.24 |
| Sharpe Ratio 12m | -0.58 |
| Alpha | 0.20 |
| Beta | 0.434 |
| Volatility | 35.68% |
| Current Volume | 124.8k |
| Average Volume 20d | 77.2k |
| Stop Loss | 8.1 (-6.4%) |
| Signal | 0.00 |
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-60.6m TTM) > 0 and > 6% of Revenue (6% = 7.42m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -1.67pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 67.27% (prev 77.23%; Δ -9.96pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 6.28m > Net Income -60.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.18 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (14.3m) change vs 12m ago -3.42% (target <= -2.0% for YES) |
| Gross Margin 38.96% (prev 61.88%; Δ -22.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 54.96% (prev 63.54%; Δ -8.58pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -34.31 (EBITDA TTM -29.1m / Interest Expense TTM 1.04m) >= 6 (WARN >= 3) |
Altman Z'' 4.46
| (A) 0.44 = (Total Current Assets 99.3m - Total Current Liabilities 16.1m) / Total Assets 187.7m |
| (B) 0.33 = Retained Earnings (Balance) 62.8m / Total Assets 187.7m |
| (C) -0.16 = EBIT TTM -35.8m / Avg Total Assets 225.2m |
| (D) 1.45 = Book Value of Equity 58.2m / Total Liabilities 40.0m |
| Total Rating: 4.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.69
| 1. Piotroski 2.0pt = -3.0 |
| 2. FCF Yield -2.35% = -1.17 |
| 3. FCF Margin -1.88% = -0.71 |
| 4. Debt/Equity 0.19 = 2.48 |
| 5. Debt/Ebitda -0.95 = -2.50 |
| 6. ROIC - WACC (= -29.32)% = -12.50 |
| 7. RoE -38.50% = -2.50 |
| 8. Rev. Trend -71.07% = -5.33 |
| 9. EPS Trend 18.38% = 0.92 |
What is the price of ANIK shares?
Over the past week, the price has changed by -0.92%, over one month by -0.46%, over three months by -22.14% and over the past year by -65.21%.
Is Anika Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ANIK is around 5.43 USD . This means that ANIK is currently overvalued and has a potential downside of -37.23%.
Is ANIK a buy, sell or hold?
- Strong Buy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ANIK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 17.3 | 100.3% |
| Analysts Target Price | 17.3 | 100.3% |
| ValueRay Target Price | 6 | -31.2% |
Last update: 2025-09-13 04:30
ANIK Fundamental Data Overview
CCE Cash And Equivalents = 53.2m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 47.8469
P/S = 1.0913
P/B = 0.8426
P/EG = 4.7944
Beta = 0.63
Revenue TTM = 123.7m USD
EBIT TTM = -35.8m USD
EBITDA TTM = -29.1m USD
Long Term Debt = 23.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.63m USD (from shortTermDebt, last quarter)
Debt = 27.6m USD (Calculated: Short Term 3.63m + Long Term 23.9m)
Net Debt = -28.2m USD (from netDebt column, last quarter)
Enterprise Value = 99.4m USD (125.0m + Debt 27.6m - CCE 53.2m)
Interest Coverage Ratio = -34.31 (Ebit TTM -35.8m / Interest Expense TTM 1.04m)
FCF Yield = -2.35% (FCF TTM -2.33m / Enterprise Value 99.4m)
FCF Margin = -1.88% (FCF TTM -2.33m / Revenue TTM 123.7m)
Net Margin = -48.99% (Net Income TTM -60.6m / Revenue TTM 123.7m)
Gross Margin = 38.96% ((Revenue TTM 123.7m - Cost of Revenue TTM 75.5m) / Revenue TTM)
Tobins Q-Ratio = 1.71 (Enterprise Value 99.4m / Book Value Of Equity 58.2m)
Interest Expense / Debt = 2.28% (Interest Expense 629.0k / Debt 27.6m)
Taxrate = 21.0% (US default)
NOPAT = -35.8m (EBIT -35.8m, no tax applied on loss)
Current Ratio = 6.18 (Total Current Assets 99.3m / Total Current Liabilities 16.1m)
Debt / Equity = 0.19 (Debt 27.6m / last Quarter total Stockholder Equity 147.7m)
Debt / EBITDA = -0.95 (Net Debt -28.2m / EBITDA -29.1m)
Debt / FCF = -11.82 (Debt 27.6m / FCF TTM -2.33m)
Total Stockholder Equity = 157.5m (last 4 quarters mean)
RoA = -32.30% (Net Income -60.6m, Total Assets 187.7m )
RoE = -38.50% (Net Income TTM -60.6m / Total Stockholder Equity 157.5m)
RoCE = -19.75% (Ebit -35.8m / (Equity 157.5m + L.T.Debt 23.9m))
RoIC = -22.75% (NOPAT -35.8m / Invested Capital 157.5m)
WACC = 6.57% (E(125.0m)/V(152.6m) * Re(7.62%)) + (D(27.6m)/V(152.6m) * Rd(2.28%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 15.15 | Cagr: -0.17%
Discount Rate = 7.62% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow -2.33m)
EPS Correlation: 18.38 | EPS CAGR: 0.17% | SUE: -0.04 | # QB: 0
Revenue Correlation: -71.07 | Revenue CAGR: -12.13% | SUE: N/A | # QB: None
Additional Sources for ANIK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle